Akheruzzaman, Md http://orcid.org/0000-0003-4639-5581
Hegde, Vijay http://orcid.org/0000-0003-4160-2764
Siddik, Md Abu Bakkar
Feizy, Zahra http://orcid.org/0000-0001-7116-0923
Shin, Andrew C. http://orcid.org/0000-0002-4748-5135
Dhurandhar, Nikhil V. http://orcid.org/0000-0002-1356-1064
Article History
Received: 2 September 2021
Revised: 2 December 2021
Accepted: 29 December 2021
First Online: 12 January 2022
Competing interests
: NVD has received several patents in viral obesity and adenovirus 36, including uses for E1A, E4ORF1 gene and protein, and AKT1inhibitor, and has received past grant support from Vital Health Interventions for determining anti-diabetic properties of E4‐ORF1 protein. Drs. Dhurandhar and Hegde recently received funding from Insparin Inc, which is a company created to advance the development of E4orf1 as a therapeutic agent. NVD owns shares in Insparin Ins. Funding from Insparin was not received for this study. Other authors did not have any conflict of interest.